ACTU - NASDAQ

Actuate Therapeutics Inc

ACTU·NASDAQ

$2.11

-4.5%

HealthcareBiotechnology

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$50.48M

EPS-1.0600

P/E Ratio-5.79

Earnings Date06/03/2026

actu

Net Interest Income

Last Annual Value

267.46K

3-Year CAGR

191%

5-Year CAGR

90%

10-Year CAGR

38%

Adjust for Inflation

Actuate Therapeutics Inc Competitors Analysis of Net Interest Income

ACTU · NASDAQ

Company	Net Interest Income	CAGR 3Y	CAGR 5Y	CAGR 10Y
Actuate Therapeutics Inc NASDAQ:ACTU	267.46K	-4.7%	N/A	N/A
Cardiff Oncology, Inc. NASDAQ:CRDF	3.10M	-8.6%	63.7%	N/A
Fate Therapeutics, Inc. NASDAQ:FATE	11.05M	-13.7%	53.2%	N/A
Forte Biosciences, Inc. NASDAQ:FBRX	2.71M	34.2%	N/A	N/A
Spero Therapeutics, Inc. NASDAQ:SPRO	2.51M	-13.9%	N/A	N/A
Elicio Therapeutics, Inc. NASDAQ:ELTX	-357.00K	N/A	N/A	N/A
Seres Therapeutics, Inc. NASDAQ:MCRB	2.23M	N/A	N/A	5.9%
Applied Therapeutics, Inc. NASDAQ:APLT	3.53M	37.1%	N/A	N/A
Alector, Inc. NASDAQ:ALEC	0.00	N/A	N/A	N/A
VistaGen Therapeutics, Inc. NASDAQ:VTGN	4.56M	459.6%	369.4%	N/A
Nkarta, Inc. NASDAQ:NKTX	15.49M	3.2%	111.1%	N/A

Actuate Therapeutics Inc Fair Value Envelope

ACTU · NASDAQ

Our analysis suggests that ACTU has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.11, this represents a potential HIDDEN relative to our calculated worth for Actuate Therapeutics Inc.

HIDDEN

Intrinsic Value

Current Price: $2.11

Related Guides

Blog Categories

Continue your ACTU research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.